Tag Archives: Sanford C. Bernstein

Novartis teams up with Allergan in NASH gamble; heated race to riches in full swing

The News: Allergan PLC (Dublin IRL) is expanding its research and development program on non-alcoholic steatohepatitis (NASH) through a collaboration with Novartis AG (Basel CHE) that will test a new… Read more »

Allergan wraps up 2016 M&A with LifeCell buy for $2.9 billion; analysts lavish kudos all around

Dublin-based Allergan said on December 19, 2016 it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP (San Antonio TX), for $2.9 billion in cash, bringing… Read more »

Novartis slowly, quietly imploding; will Alcon, Amneal moves halt spiral?

Renewed whispers from Swiss drugmaker Novartis AG (Basel) that it could divest its struggling Alcon eyecare business reflect the latest step in dismantling former leader Dan Vasella’s vision of building… Read more »

Bristol Myers Clobbered as Cancer Drug Disappoints; Rival Merck Unanimous Winner at Medical Conference

New data are likely to prompt doctors to abandon Bristol-Myers Squibb Co.’s (New York City) immunotherapy Opdivo in favor of Merck & Co.’s (Kenilworth NJ) rival Keytruda in a large… Read more »

Mylan Agrees to $465 Million EpiPen Settlement with US; But the Matter is Far From Over

Mylan NV (Amsterdam) will pay the US government $465 million in a swift settlement over how the drugmaker charged Medicaid for its allergy shot EpiPen, according to Bloomberg News. The… Read more »

Mylan Plans Generic EpiPen to Calm Pricing Outrage; Feels More Like a PR Move

Mylan NV’s latest attempt to deflect criticism over the price of allergy shot EpiPen failed to get the drugmaker out of the crosshairs of Congress this week. Last week, Chief… Read more »